Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Amutha Rajagopal

Internal Medicine Portland, OR Medical Doctor

NPI 1124465745 CMS profile 1379938

3181 Sw Sam Jackson Park Rd, Portland, OR 97239

Open in the dashboard

General payments

$1,699

86 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Amutha Rajagopal of Portland, OR is reported in the CMS Open Payments database as having received $1,699 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $134 2
2022 General $890 34
2021 General $558 49
2019 General $116 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amutha Rajagopal
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Amutha Rajagopal were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Amutha Rajagopal Internal Medicine median Middle half National median
2019 $116 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $558 $135 $37–$521 $132
2022 $890 $141 $42–$496 $149
2023 $134 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Abbott Laboratories $937 18 payments
  2. Janssen Biotech, Inc. $645 67 payments
  3. Gilead Sciences, Inc. $116 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,699 86 payments
Products named General payments · program years 2019–2023
  1. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $716 8 payments
  2. SYMTUZA $645 67 payments
  3. HeartMate 3 Left Ventricular Assist Device $222 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 83 drugs

Part D claims

2,736

Median for Infectious Disease: 268

Drug cost

$2,508,945

Median for Infectious Disease: $217,595

Branded share of claims

50.3%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 309 $1,176,381
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 56 $257,206
Cabenuva Cabotegravir/Rilpivirine Brand 36 $208,657
Pifeltro Doravirine Brand 87 $152,535
Odefsey Emtricitab/Rilpiviri/Tenof Ala Brand 36 $145,326
Dovato Dolutegravir Sodium/Lamivudine Brand 51 $143,709
Descovy Emtricitabine/Tenofov Alafenam Brand 41 $97,775
Vivitrol Naltrexone Microspheres Brand 48 $75,206
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 11 $48,931
Mounjaro Tirzepatide Brand 45 $45,977

The 10 drugs with the highest cost, of 83 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$14,045

Medicare's payments for the services billed

Medicare patients

69

Average age 65

Services billed

180

22 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 49%
Arthritis 46%
Chronic kidney disease 42%
Diabetes 36%
Ischemic heart disease 35%
Heart failure 30%
Osteoporosis 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record